NIH Scientists Find Weak Points on Epstein-Barr Virus New Details of EBV Protein Could Aid Treatment, Prevention Efforts

https://www.niaid.nih.gov/news-events/nih-scientists-find-weak-points-epstein-barr-virus?utm_campaign=+59782124&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term= Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus, which can cause B-cell cancers and is associated with multiple sclerosis. The research was led by Jeffrey I. Cohen, M.D., and colleagues from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.